Oncopeptides (ONCO) Aktievy
Oncopeptides AB (publ) är ett bioteknikföretag som bedriver forskning, utveckling och kommersialisering av riktade behandlingar för svårbehandlade hematologiska sjukdomar i USA, Europa och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 3/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
ONCO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
SEK 2.56
FV
38.2% undervärderad intrinsisk rabatt62
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
Oncopeptides AB (publ) Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | SEK 1.58 |
| 52 veckors högsta | SEK 6.96 |
| 52 veckors lägsta | SEK 1.26 |
| Beta | -1.31 |
| 1 månads förändring | -7.54% |
| 3 månaders förändring | 17.01% |
| 1 års förändring | -65.46% |
| 3 års förändring | -82.75% |
| 5 års förändring | -97.32% |
| Förändring sedan börsintroduktionen | -96.32% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 09
ONCO: Expanded Multiple Myeloma Reach Will Drive Future Risk Reward Repricing
Analysts have cut their price target on Oncopeptides to SEK2.10 from SEK4.50, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, and a higher projected profit margin paired with a lower future P/E multiple. What’s in the News for Oncopeptides Oncopeptides enrolled the first patient in the OP-701 INSULA "Window of Opportunity" study in glioblastoma, the first clinical evaluation of its peptide drug conjugate platform in this indication.
Uppdatering av berättelse • Jun 25
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Analysts have adjusted their price target on Oncopeptides to SEK 3.10 from SEK 5.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Oncopeptides First patient enrolled in the OP-701 INSULA "Window-of-Opportunity" study in glioblastoma, the first clinical evaluation of Oncopeptides' PDC platform in this cancer, aiming to assess blood brain barrier penetration and tumor cell activity; the trial is being conducted at Oslo University Hospital in Norway.Recent updates
Uppdatering av berättelse • Jul 09
ONCO: Expanded Multiple Myeloma Reach Will Drive Future Risk Reward Repricing
Analysts have cut their price target on Oncopeptides to SEK2.10 from SEK4.50, citing updated assumptions for fair value, a higher discount rate, more moderate revenue growth, and a higher projected profit margin paired with a lower future P/E multiple. What’s in the News for Oncopeptides Oncopeptides enrolled the first patient in the OP-701 INSULA "Window of Opportunity" study in glioblastoma, the first clinical evaluation of its peptide drug conjugate platform in this indication.Uppdatering av berättelse • Jun 25
ONCO: Expanded Multiple Myeloma Indication Will Drive Long-Term Upside
Analysts have adjusted their price target on Oncopeptides to SEK 3.10 from SEK 5.50, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E. What's in the News for Oncopeptides First patient enrolled in the OP-701 INSULA "Window-of-Opportunity" study in glioblastoma, the first clinical evaluation of Oncopeptides' PDC platform in this cancer, aiming to assess blood brain barrier penetration and tumor cell activity; the trial is being conducted at Oslo University Hospital in Norway.
Uppdatering av berättelse • Apr 29
ONCO: Rights Issue And Glioblastoma Study Will Support Bullish Long Term View
Analysts have maintained their SEK fair value estimate for Oncopeptides at SEK 2.80, while fine tuning assumptions for the discount rate, profit margin, and future P/E. This reflects updated views on the company’s risk profile and earnings potential without changing the headline price target.Uppdatering av berättelse • Apr 12
ONCO: Rights Issue And New Studies Will Support Bullish Long Term View
Analysts have modestly adjusted their SEK price target for Oncopeptides, reflecting small refinements to discount rate, profit margin assumptions, and future P/E inputs rather than a shift in the core fair value view. What's in the News Oncopeptides plans to support the MARINA real world evidence study of Pepaxti in relapsed, refractory multiple myeloma in Germany, targeting around 50 patients across about 25 sites, with iOMEDICO as sponsor and coordinator and first patient enrolment planned for the second quarter of 2026 (Key Developments).Uppdatering av berättelse • Mar 28
ONCO: Rights Offering And 2025 Sales Guidance Will Support Bullish View
Analysts have kept their SEK price target for Oncopeptides effectively unchanged, pointing to stable fair value assumptions and only marginal tweaks to inputs such as the discount rate, forecast revenue growth, profit margin and future P/E multiple. What's in the News Oncopeptides has filed a follow on equity offering of Ordinary Shares, targeting SEK 200.4 million through a rights offering of 129,283,736 shares at SEK 1.55 per share (Key Developments).Uppdatering av berättelse • Mar 12
ONCO: Rights Issue And 2025 Sales Outlook Will Support Bullish View
Analysts have adjusted their price target on Oncopeptides to SEK 2.80. The change is largely tied to updated assumptions around the discount rate, profit margin, and future P/E, rather than a shift in estimated fair value.Uppdatering av berättelse • Feb 25
ONCO: Rights Issue And 2025 Sales Guidance Will Support Bullish Outlook
Analysts have trimmed their price target on Oncopeptides to SEK 2.80 from SEK 4.75, reflecting updated assumptions for slightly lower revenue growth, a marginally softer profit margin, a higher discount rate, and a reduced future P/E multiple. What's in the News Oncopeptides AB (publ) has filed a follow on equity offering of approximately SEK 200.4m through a rights offering of 129,283,736 ordinary shares at SEK 1.55 per share (Key Developments).Uppdatering av berättelse • Feb 09
ONCO: Future Sales Guidance Will Support Bullish View On Upcoming Results
Analysts have cut their price target on Oncopeptides to €4.75 from €5.50, reflecting updated assumptions around revenue growth, profit margins, a higher discount rate, and a higher future P/E multiple. What's in the News Oncopeptides issued sales guidance for the fourth quarter 2025.Uppdatering av berättelse • Jan 25
ONCO: NK Cell Platform Progress Will Drive Future Risk Reward Repricing
Analysts have reduced their price target for Oncopeptides from 5.0 to 4.5, reflecting a fair value adjustment driven by shifts in projected revenue growth, higher discount rates, stronger profit margin assumptions, and a lower future P/E estimate. What's in the News Oncopeptides issued sales guidance for the fourth quarter and full year 2025, with expected Q4 2025 net sales of SEK 18.6 million and full year 2025 net sales of SEK 71.2 million, both described by the company as higher compared with 2024 (Corporate guidance).Uppdatering av berättelse • Jan 11
ONCO: NK Cell Platform Progress And Expert Guidance Will Shape Future Risk Reward
Analysts have modestly lowered their future P/E assumption for Oncopeptides from 38.59x to 36.58x, keeping fair value at €5.00. They have fine tuned expectations for revenue growth and profit margins while making a slight adjustment to the discount rate.Uppdatering av berättelse • Dec 26
ONCO: Improved Profitability And NK Cell Platform Will Drive Long-Term Upside
Analysts have raised their price target on Oncopeptides from approximately SEK 4.50 to SEK 5.50 per share, citing expectations of stronger long term profitability, supported by higher projected profit margins and a lower future price to earnings multiple, despite slightly tempered revenue growth assumptions and a modestly higher discount rate. What's in the News Panel of leading multiple myeloma experts publishes clinical recommendations in Annals of Hematology on optimal use of Pepaxti (melflufen), reinforcing its role as an important option for relapsed, refractory multiple myeloma, including elderly and high risk patients, with a manageable safety profile (company announcement).Uppdatering av berättelse • Dec 12
ONCO: Future NK Platform And Equity Raise Will Shape Risk Reward Profile
Analysts have modestly raised their price target on Oncopeptides to align with a fair value approaching $5.00 per share, citing a higher required discount rate, more conservative revenue growth and margin assumptions, and a structurally higher future P/E multiple. Taken together, these factors imply a more cautiously optimistic risk reward profile.Uppdatering av berättelse • Aug 20
Agreements In Europe And Japan Will Unlock Global Markets
The notable increase in Oncopeptides' fair value target is primarily driven by a higher forecasted future P/E multiple, despite a marginal dip in revenue growth expectations, with the analyst consensus price target rising from SEK2.73 to SEK3.25. What's in the News Strategic partnership with SD Pharma enhances Pepaxti's hospital reach in Spain without upfront costs, starting Q3 2025.Analysartikel • Jul 28
A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
Key Insights Oncopeptides' estimated fair value is kr5.77 based on Dividend Discount Model Oncopeptides' kr6.00 share...
Ny berättelse • Apr 15
Agreements In Europe And Japan Will Unlock Global Markets
Strategic agreements in Europe and potential licensing in Japan will unlock major markets, enhancing future earnings and revenue growth.Analysartikel • Jun 18
An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued
Key Insights Using the Dividend Discount Model, Oncopeptides fair value estimate is kr5.43 Oncopeptides is estimated to...Analysartikel • Feb 29
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analysartikel • Nov 14
Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktieägarnas avkastning
| ONCO | SE Biotechs | SE Marknad | |
|---|---|---|---|
| 7D | -3.8% | 0.5% | -1.3% |
| 1Y | -65.5% | 29.4% | 8.6% |
Avkastning vs industri: ONCO presterade sämre än Swedish Biotechs branschen som gav 29.4 % under det senaste året.
Avkastning vs Marknaden: ONCO presterade sämre än Swedish marknaden som gav 8.6 % under det senaste året.
Prisvolatilitet
| ONCO volatility | |
|---|---|
| ONCO Average Weekly Movement | 13.9% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.5% |
Stabil aktiekurs: ONCO s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för Swedish.
Volatilitet över tid: ONCO s veckovolatilitet ( 14% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av Swedish aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2000 | 77 | Sofia Heigis | www.oncopeptides.com/sv |
Oncopeptides AB (publ) är ett bioteknikföretag som bedriver forskning, utveckling och kommersialisering av målinriktade behandlingar för svårbehandlade hematologiska sjukdomar i USA, Europa och internationellt. Bolagets ledande produktkandidat är Pepaxti (melflufen), en läkemedelskonjugat för behandling av relapserande och refraktärt multipelt myelom hos vuxna patienter. Bolagets PDC-plattform är utformad med två komponenter, en peptidbärare och en cytotoxisk nyttolast, som utnyttjar cancercellernas förändrade metabolism för att hydrolysera PDC till aktiva hydrofila metaboliter, vilket leder till en anrikning i cancerceller.
Oncopeptides AB (publ) Sammanfattning av grunderna
| ONCO grundläggande statistik | |
|---|---|
| Börsvärde | SEK 625.34m |
| Vinst(TTM) | -SEK 221.10m |
| Intäkter(TTM) | SEK 83.24m |
7.5x
P/S-förhållande-2.8x
P/E-förhållandeÄr ONCO övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| ONCO resultaträkning (TTM) | |
|---|---|
| Intäkter | SEK 83.24m |
| Kostnad för intäkter | SEK 2.86m |
| Bruttovinst | SEK 80.38m |
| Övriga kostnader | SEK 301.48m |
| Intäkter | -SEK 221.10m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
Aug 27, 2026
| Vinst per aktie (EPS) | -0.56 |
| Bruttomarginal | 96.57% |
| Nettovinstmarginal | -265.63% |
| Skuld/egenkapitalförhållande | 170.3% |
Hur har ONCO utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/09 02:18 |
| Aktiekurs vid dagens slut | 2026/07/09 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Oncopeptides AB (publ) bevakas av 7 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Erik Hultgård | Carnegie Investment Bank AB |
| Patrik Ling | DNB Carnegie |
| Erik Hultgård | DNB Carnegie |